← Adaptive Biotechnologies Corp
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $55.0m | $96.6m | $123.4m | $139.1m | $90.0m | $65.1m | $47.9m | $70.5m | |
| Accounts receivable, net | $4.8m | $12.7m | $10.0m | $17.4m | $40.1m | $38.0m | $41.7m | $50.4m | |
| Inventory | $7.8m | $9.1m | $14.1m | $19.3m | $14.5m | $14.4m | $8.4m | $9.8m | |
| Prepaid expenses and other current assets | $3.1m | $14.1m | $14.5m | $13.0m | $9.4m | $11.4m | $11.3m | $13.0m | |
| Total current assets | $180.7m | $612.7m | $726.9m | $402.7m | $562.1m | $410.2m | $283.8m | $300.2m | |
| Property and equipment, net | $19.1m | $60.4m | $39.7m | $85.3m | $83.4m | $68.2m | $48.6m | $34.1m | |
| Intangible assets, net | $13.6m | $11.9m | $10.2m | $8.5m | $6.8m | $5.1m | $3.4m | $1.7m | |
| Goodwill | $119.0m | $119.0m | $119.0m | $119.0m | $119.0m | $119.0m | $119.0m | $119.0m | |
| Operating lease right-of-use assets | — | — | $99.3m | $87.7m | $80.8m | $52.1m | $45.8m | $40.6m | |
| Other assets | $186k | $784k | $598k | $875k | $2.1m | $3.6m | $2.3m | $1.2m | |
| Short-term marketable securities (amortized cost of $156,246 and $174,186, respectively) | $110.0m | $480.3m | $564.8m | $214.0m | $408.2m | $281.3m | $174.4m | $156.5m | |
| Long-term marketable securities (amortized cost of $13,220 and $33,682, respectively) | — | $105.4m | $118.5m | $217.1m | — | $130.7m | $33.7m | $13.2m | |
| Restricted cash | $61k | $2.1m | $2.1m | $2.1m | $2.4m | $2.9m | $2.9m | $2.7m | |
| Current portion of operating lease liabilities | — | — | $3.5m | $5.1m | $9.2m | $9.4m | $10.2m | $8.9m | |
| Current portion of revenue interest liability, net | — | — | — | — | — | — | $865k | $4.6m | |
| Operating lease liabilities, less current portion | — | — | $104.3m | $106.7m | $98.8m | $89.4m | $79.1m | $70.2m | |
| Revenue interest liability, net, less current portion | — | — | — | — | $125.4m | $130.7m | $132.4m | $126.6m | |
| Total Adaptive Biotechnologies Corporation shareholders’ equity | ($258.1m) | $571.0m | $743.3m | $604.0m | $464.2m | $308.4m | $202.7m | $218.8m | |
| Total shareholders’ equity | — | — | $743.3m | $604.1m | $464.1m | $308.3m | $202.5m | $225.0m | |
| Total assets | $332.7m | $912.3m | $1.1b | $923.3m | $856.6m | $661.1m | $539.4m | $512.7m | |
| Accounts payable | $1.8m | $4.5m | $3.2m | $3.3m | $8.1m | $7.7m | $7.3m | $6.5m | |
| Accrued liabilities | $2.6m | $4.4m | $13.2m | $9.3m | $12.4m | $8.6m | $8.2m | $7.7m | |
| Accrued compensation and benefits | $4.6m | $8.1m | $11.9m | $15.6m | $15.9m | $13.7m | $15.8m | $17.0m | |
| Current portion of deferred revenue | $12.7m | $61.0m | $73.3m | $80.5m | $64.1m | $48.6m | $55.7m | $45.2m | |
| Deferred revenue, less current portion | $704k | $219.3m | $163.6m | $98.8m | $58.6m | $44.8m | $27.3m | $1.0m | |
| Total current liabilities | $22.8m | $78.3m | $105.2m | $113.8m | $109.8m | $88.0m | $98.1m | $89.9m | |
| Other long-term liabilities | — | $93k | — | — | — | — | $20k | $20k | |
| Total liabilities | $29.9m | $341.3m | $373.1m | $319.2m | $392.5m | $352.9m | $336.9m | $287.7m | |
| Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2025 and 2024; 153,779,418 and 147,773,744 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1k | 12k | 14k | 14k | 14k | 14k | 14k | 15k | |
| Additional paid-in capital | $37.9m | $935.8m | $1.3b | $1.3b | $1.4b | $1.5b | $1.5b | $1.6b | |
| Accumulated other comprehensive gain | ($107k) | $671k | $893k | ($1.1m) | ($4.1m) | $215k | $166k | $253k | |
| Accumulated deficit | ($295.9m) | ($365.5m) | ($511.6m) | ($718.9m) | ($919.1m) | ($1.1b) | ($1.3b) | ($1.4b) | |
| Noncontrolling interest | — | — | — | $110k | ($67k) | ($121k) | ($224k) | $6.2m | |
| Total liabilities and shareholders’ equity | $332.7m | $912.3m | $1.1b | $923.3m | $856.6m | $661.1m | $539.4m | $512.7m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.